secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001493152-25-005563
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance
--------------------------------------------------------------------------------

- Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.
- Five largest shareholders led round, including strategic partner Bio-Rad Laboratories (NYSE: BIO).
- Proceeds expected to fully fund FDA IVD clearance and commercial launch of proprietary transplant assay.
- Terminated at-the-market Sales Agreement with Needham; $1.8M previously sold under it.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225005563/0001493152-25-005563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315225005563/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer